Education
About Us
Working with TipRanks
Follow Us
Mediwound (MDWD)
NASDAQ:MDWD
Top Page
Mediwound
(NASDAQ:MDWD)
Rating:50Neutral
Price Target:―
Positive Factors
Funding
MediWound received €16.5 million in funding from the European Innovation Council to accelerate the development of EscharEx.
Market Opportunity
EscharEx is being developed for enzymatic debridement of chronic wounds, representing a potential $2.5 billion market opportunity.
Product Rollout
NexoBrid's US rollout by partner Vericel continues to build momentum, as Vericel reported revenue increases for the product.
Negative Factors
Guidance Adjustment
NexoBrid guidance tightened towards lower end, reflecting adjusted timelines for EU approval of the manufacturing facility.
Revenue Performance
Revenue in 1Q totaled $4.0 million, down from $5.0 million and below the Street's $5.2 million expectation.
Supply Limitations
Global demand for NexoBrid currently exceeds MDWD's manufacturing capacity, limiting sales despite high demand.
Mediwound (MDWD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$221.67M
Dividend YieldN/A
Average Volume (3M)72.93K
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue Growth-3.21%
EPS Growth-51.08%
CountryUS
Employees111
SectorHealthcare
Sector Strength44
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.07
Shares Outstanding10,807,726
10 Day Avg. Volume100,626
30 Day Avg. Volume72,934
Financial Highlights & Ratios
PEG Ratio0.97
Price to Book (P/B)5.52
Price to Sales (P/S)0.00
P/FCF Ratio-9.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$27.67Price Target Upside39.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Mediwound Business Overview & Revenue Model
Company DescriptionMediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
How the Company Makes MoneyMediwound makes money primarily through the sales of its proprietary products like NexoBrid. The company's revenue model is based on direct sales to healthcare facilities, partnerships with distributors, and licensing agreements. Mediwound collaborates with governmental and non-governmental organizations for the procurement of its products, which contributes significantly to its earnings. Additionally, the company benefits from various grants, research collaborations, and milestone payments from strategic partnerships aimed at expanding the application of its technologies.
Mediwound Financial Statement Overview
Summary
Mediwound faces significant financial challenges with persistent losses and cash flow issues. While debt remains manageable, the negative equity and inconsistent revenue growth present long-term sustainability risks. The company needs to improve profitability and operational efficiency to enhance its financial health.Income Statement
Mediwound's income statement reveals a challenging financial position with consistent net losses. The gross profit margin has significantly declined from historical levels, indicating a struggle in maintaining profitability. The net profit margin is negative, reflecting substantial net losses. Revenue growth is inconsistent, with a recent decline after a previous increase. EBIT and EBITDA margins are also negative, showing operational inefficiencies.45
Neutral
Balance Sheet
The balance sheet shows a moderate financial stability with a manageable debt-to-equity ratio due to relatively low total debt. However, the return on equity is negative due to consecutive net losses, impacting stockholders' equity. The equity ratio indicates a reasonable portion of assets funded by equity, but decreasing equity over time poses a risk.50
Neutral
Cash Flow
Mediwound's cash flow statement highlights negative free cash flow, indicating cash outflows exceeding inflows. The operating cash flow to net income ratio is negative, consistent with the company's losses. The free cash flow to net income ratio also reflects operational and capital expenditure challenges. Cash flow issues underline sustainability concerns.40
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 20.22M | 18.69M | 26.50M | 23.76M | 21.76M | Gross Profit |
| 2.63M | 3.58M | 13.16M | 8.77M | 7.54M | EBIT |
| -19.40M | -15.29M | -8.35M | -11.22M | -8.84M | EBITDA |
| -27.93M | -4.89M | -18.09M | -11.22M | -7.75M | Net Income Common Stockholders |
| -30.22M | -6.72M | -19.60M | -13.55M | -9.60M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 9.15M | 41.54M | 33.90M | 11.05M | 21.58M | Total Assets |
| 73.50M | 66.46M | 50.02M | 19.74M | 31.07M | Total Debt |
| 6.51M | 6.35M | 846.00K | 1.39M | 1.74M | Net Debt |
| -2.64M | -5.52M | -33.05M | -9.65M | -15.63M | Total Liabilities |
| 42.34M | 34.86M | 39.10M | 24.33M | 23.80M | Stockholders Equity |
| 31.15M | 31.59M | 10.91M | -4.58M | 7.27M |
| Cash Flow | Free Cash Flow | |||
| -19.90M | -16.93M | -12.44M | -9.40M | -7.82M | Operating Cash Flow |
| -13.62M | -10.46M | -11.88M | -8.92M | -6.89M | Investing Cash Flow |
| -8.40M | -34.32M | -481.00K | 3.55M | 17.39M | Financing Cash Flow |
| 19.39M | 22.92M | 35.76M | -1.05M | -629.00K |
Mediwound Technical Analysis
Positive
19.89
Price Trends
17.53
Positive
17.79
Positive
17.61
Positive
Market Momentum
0.87
Negative
61.27
Neutral
86.25
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDWD, the sentiment is Positive. The current price of 19.89 is above the 20-day moving average (MA) of 18.64, above the 50-day MA of 17.53, and above the 200-day MA of 17.61, indicating a bullish trend. The MACD of 0.87 indicates Negative momentum. The RSI at 61.27 is Neutral, neither overbought nor oversold. The STOCH value of 86.25 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MDWD.
Mediwound Risk Analysis
Mediwound disclosed 58 risk factors in its most recent earnings report. Mediwound reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Mediwound Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $205.41M | 48.01 | 7.41% | ― | 26.86% | ― | |
59 Neutral | $207.99M | 130.51 | 2.17% | ― | 134.52% | ― | |
53 Neutral | $5.24B | 3.07 | -43.58% | 2.80% | 16.87% | -0.11% | |
51 Neutral | $225.83M | ― | -17.22% | ― | -22.93% | -65.68% | |
50 Neutral | $221.67M | ― | -96.33% | ― | -3.21% | -51.08% | |
45 Neutral | $168.58M | ― | -14.10% | ― | 5.73% | 72.50% | |
38 Underperform | $261.92M | ― | -47.95% | ― | ― | -8.07% |
* Healthcare Sector Average
Performance Comparison
MDWD
Mediwound
19.89
2.28
12.95%
AMRN
Amarin
10.98
-6.46
-37.04%
INGN
Inogen
5.96
-2.68
-31.02%
GNFT
Genfit SA
4.35
-0.09
-2.03%
BWAY
Brainsway
10.40
4.93
90.13%
DRTS
Alpha Tau Medical Ltd
3.11
0.40
14.76%
Mediwound Earnings Call Summary
Earnings Call Date:May 21, 2025
(Q1-2025)
| % Change Since: -4.70%|
Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed outlook for MediWound. While there are significant advancements in clinical trials and strategic collaborations, financial metrics reveal challenges with declining revenue and increased losses. However, the strong growth in NexoBrid's adoption and the strategic initiatives for EscharEx show promise for future performance.Q1-2025 Updates
Positive Updates
Strong Phase III Progress for EscharEx
The VALUE Phase III study for EscharEx is on track with recruitment for venous leg ulcers progressing as planned. The trial will enroll 216 patients across 40 sites in the US and Europe, with results expected to support regulatory submissions and commercial positioning.
NexoBrid Global Expansion
US adoption of NexoBrid continues to expand with a 207% year-over-year increase and a 31% sequential increase in revenue. There is high demand in Japan and Europe, with manufacturing capacity expansion underway.
Strategic Collaborations
Collaboration with major wound care companies, including Kerecis, Mölnlycke, and MIMEDX, adds significant validation to MediWound's clinical programs, particularly for EscharEx.
European Innovation Council Grant
Secured a EUR2.5 million grant component for the clinical and regulatory advancement of EscharEx for diabetic foot ulcers.
Negative Updates
Decline in Total Revenue
Total revenue for Q1 2025 was $4 million, down from $5 million in Q1 2024, primarily due to lower BARDA-funded development services revenue.
Increased Operating and Net Loss
Operating loss for the quarter was $5.2 million compared to $3.7 million in Q1 2024. Net loss was $0.7 million compared to a net loss of $9.7 million last year.
Reduced Cash Reserves
Cash, cash equivalents, and deposits decreased from $43.6 million at year-end 2024 to $38.7 million as of March 31, 2025.
Company Guidance
During the MediWound First Quarter 2025 Earnings Call, the company provided several performance metrics and guidance updates. MediWound reported a total revenue of $4 million for the first quarter, down from $5 million in Q1 2024, with a gross profit of $0.7 million, reflecting a gross margin of 19%. Research and development expenses increased to $2.9 million due to ongoing investment in the EscharEx VALUE Phase III trial. The operating loss for the quarter was $5.2 million, while the net loss was $0.7 million or $0.07 per share, significantly improved from a net loss of $9.7 million or $1.05 per share in the prior year, primarily due to non-cash financial income from warrant revaluation. As of March 31, 2025, the company held $38.7 million in cash and equivalents, using $5.1 million to fund operations during the quarter. Looking forward, the company is on track with its clinical trials and manufacturing expansions, expecting EscharEx's interim analysis by mid-2026, while anticipating commercial availability of NexoBrid from the new facility by 2026, post regulatory approvals.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.